Nootropic alpha7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators

Area of Science:

• Neuroscience
• Pharmacology
• Medicinal Chemistry

Background:

• Alpha7 nicotinic acetylcholine receptors (alpha7 nAChRs) are key therapeutic targets for central nervous system (CNS) diseases characterized by cognitive dysfunction, such as Alzheimer's disease and schizophrenia.
• Positive allosteric modulation (PAM) of alpha7 nAChRs offers a promising therapeutic strategy, potentially delivering clinical benefits with improved safety profiles compared to direct agonists.

Purpose of the Study:

• To identify and characterize a novel selective positive allosteric modulator (PAM) for alpha7 nicotinic acetylcholine receptors (alpha7 nAChRs).
• To evaluate the therapeutic potential of the identified PAM in preclinical models of cognitive dysfunction.

Main Methods:

• Screening of a GABAA receptor PAM library to identify compounds with alpha7 nAChR activity.
• Electrophysiological assessment of compound 6's modulatory effects on agonist-induced currents at alpha7 nAChRs.
• Evaluation of compound 6's efficacy in rodent models assessing sensory gating and working memory.

Main Results:

• Compound 6, a selective alpha7 nAChR PAM, demonstrated robust positive modulation of agonist-induced currents while preserving native desensitization kinetics.
• Compound 6 exhibited minimal activity at other ligand-gated ion channels, indicating high selectivity.
• In rodent models, compound 6 corrected sensory-gating deficits and improved working memory, consistent with cognitive enhancement.

Conclusions:

• Compound 6 represents a novel chemotype for the allosteric activation of alpha7 nAChRs.
• This compound shows significant therapeutic potential for treating CNS diseases associated with cognitive dysfunction.